Anti-EGFR monoclonal antibodies regulatory update

IMCL received U.S. Patent No. 6,217,866 covering the use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) in combination with anti-neoplastic agents to treat cancer. The p...